Evidence map›Paper›PMID 35528162›Full record

ArticleBioMed research international2022

The Effect of Oral Mucosal Mesenchymal Stem Cells on Pathological and Long-Term Outcomes in Experimental Traumatic Brain Injury.

Fatemeh Dehghanian, Zahra Soltani, Alireza Farsinejad, Mohammad Khaksari, Elham Jafari, Ali Darakhshani, Nazanin Sabet, Hamideh Bashiri

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Therapeutic Scope of Orofacial Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fatemeh DehghanianNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-4016-2210
Zahra SoltaniEndocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-8423-6189
Alireza FarsinejadDepartment of Hematology and Medical Laboratory Sciences, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-0276-6881
Mohammad KhaksariPhysiology and Pharmacology Department, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0003-0770-4281
Elham JafariPathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0001-9240-9177
Ali DarakhshaniPathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0001-5669-8813
Nazanin SabetEndocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0002-9549-6402
Hamideh BashiriPhysiology and Pharmacology Department, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0001-8818-0170
Kerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuroprotective effects of stem cells have been shown in some neurologic diseases. In this study, the effect of oral mucosal mesenchymal stem cells (OMSCs) on traumatic brain injury (TBI) was evaluated in long term. Materials and Methods: TBI was induced by Marmarou's method. The number of 2 × 10 Results: OMSCs administration could significantly inhibit microglia proliferation, and reduce brain edema and neuronal damage, at 24 h and 21 days after the injury. Neurological function improvement was observed in the times evaluated in OMSCs group. Cognitive and motor function dysfunction and anxiety-like behavior were prevented especially at 14 and 21 days after the injury in the treatment group. Conclusion: According to the results of this study, OMSCs administration after TBI reduced brain edema and neuronal damage, improved neurologic outcome, and prevented memory and motor impairments and anxiety-like behavior in long term.

Indexed as

Brain EdemaBrain Injuries, TraumaticMesenchymal Stem CellsNeuroprotective AgentsAnimalsDisease Models, AnimalNeurogenesisNeuroprotective Agents

Identifiers

PMID35528162
PMCPMC9071883
OpenAlexW4225009683

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.